NCT07434063 Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection
| NCT ID | NCT07434063 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hebei Medical University Fourth Hospital |
| Condition | Neutropenia |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-06-18 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-06-18 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multicenter, observational real-world study, aiming to observe and evaluate the efficacy and safety of prophylactic application of Mecapegfilgrastim Injection in tumor patients after radiotherapy/chemotherapy/immunotherapy in the real world to prevent neutropenia.The subjects who met the inclusion criteria of the protocol were defined as those who needed radiotherapy/chemotherapy/immunotherapy after being diagnosed with solid malignant tumors. The researchers believed that the subjects needed to use Mecapegfilgrastim Injection for primary/secondary prevention after receiving tumor treatment.
Eligibility Criteria
Inclusion Criteria: * 1\. Patients with malignant tumors confirmed by histopathology or cytology; 2. Age ≥18 years old; 3. After referring to various guidelines, the researchers believed that the subjects: 1. Patients who are currently receiving treatment regimens with high FN risk; 2. Patients who are currently receiving treatment regimens for moderate FN risk and meet any one of the factors that increase the risk coefficient; 3. FN or dose-limiting neutropenia events have occurred in previous treatment cycles; 4. In addition to the above, the researchers believe that the medication regimens will cause neutropenia and affect the normal treatment of the subjects; 4. Researchers believe that they can benefit; 5. Voluntarily participate in this clinical trial and be able to sign the informed consent form in person. Exclusion Criteria: * 1\. Those who are allergic to the test drug； 2. Those with mental or neurological disorders who are unable to cooperate； 3. Pregnant or lactating female patients; Women of childbearing age who refuse to take contraceptive measures； 4. Those who were considered unsuitable for inclusion by the researchers.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07434063 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neutropenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07434063 currently recruiting?
Yes, NCT07434063 is actively recruiting participants. Contact the research team at jiekejaker@sina.com for enrollment information.
Where is the NCT07434063 trial being conducted?
This trial is being conducted at Shijiazhuang, China.
Who is sponsoring the NCT07434063 clinical trial?
NCT07434063 is sponsored by Hebei Medical University Fourth Hospital. The trial plans to enroll 200 participants.